Company Name Change Effective – Molecule Group plc
Molecule Group PLC
05 October 2026
5 October 2026
Molecule Group plc
(the “Company”, "Group" or "Molecule")
Company Name Change Effective – Molecule Group plc
Vulcan Two Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, confirms the change of its name to Molecule Group plc.
Companies House issued a change of name certificate on 2 October 2026 and the name change to Molecule Group plc has become effective immediately. The Company confirms that the change of name has been notified to the London Stock Exchange and trading in the Company's shares under the new company name and new TIDM code/ticker symbol‘MOL’will commence today at 8.00 a.m.
Molecule - One Group, One Brand:
|
|
Company name change to Molecule Group plc reflects the Group’s progress into an integrated ePharmacy platform.
|
|
|
Molecule brand creates a single identity across the Group’s consumer, veterinary and professional healthcare channels.
|
|
|
New B2C website molecule.co.uk, brings together a new Molecule clinic, an enhanced over-the-counter range and our veterinary offering in a single portal. This gives the direct-to-consumer business a single modern platform, a wider basket per customer and one place in which to invest in customer acquisition and retention.
|
|
|
New investor relations website will be: investors.molecule.co.uk
|
Michael Kraftman, Chief Executive Officer of Molecule, commented:“We are delighted to launch the Molecule brand which marks an important milestone in the Group's development and provides a single identity across the Group’s consumer, veterinary and professional channels in place of a collection of acquired names, and a common focus for marketing investment.”
The Company's ISIN and SEDOL will remain unchanged.
Shareholders are unaffected by the change of name and existing share certificates should be retained and will remain valid.
For further information please contact:
|
Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Finance Officer Brendan O’Brien, Chief Operating Officer |
Email: corporate@molecule.co.uk |
|
Canaccord Genuity Limited Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott |
Tel: +44 (0) 20 7523 8000 |
|
Alma Strategic Communications Justine James / Sam Modlin / Will Merison |
Email: molecule@almastrategic.com Tel: +44 (0) 20 3405 0205 |
Notes to Editors
Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.
The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.